ArticleInternational journal of women's health2025
The Relationship between Systemic Expression Levels of Immune Cells and Tumor Markers and High-Risk HPV Infection in Patients with Cervical Cancer, Cervical Intraepithelial Neoplasia, and Chronic Cervicitis, and its Clinical Significance.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Oral Treatment with EGCG, Folic Acid, Vitamin B12, and Hyaluronic Acid Improves HPV Clearance and Counteracts Its Persistence: A Clinical Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the relationship and clinical significance between systemic expression levels of immune cells and tumor markers and high-risk human papillomavirus (HPV) infection in patients with cervical cancer, cervical intraepithelial neoplasia, and chronic cervicitis. Methods: A retrospective analysis was conducted on the clinical data of 69 patients with cervical cancer infected with HPV (Group A), 78 patients with CIN (Group B), and 52 patients with chronic cervicitis (Group C) treated at Hebei Central Hospital of petroleum gynecology from April 2021 to April 2023. Peripheral blood immune cells (CD4+/CD8+, CD56+, Treg) and serum tumor markers (CA125, SCC-Ag, TSGF, Cyfra211) were compared. Correlations with HPV-DNA levels, lymph node metastasis, and survival were analyzed. Results: Group A had lower CD4+/CD8+ and CD56+ levels but higher Treg and tumor marker levels vs Groups B/C (P<0.05). Group B showed similar trends vs Group C (P<0.05). In Group A, Treg and tumor markers positively correlated with HPV-DNA levels (r=0.552-0.613), while CD4+/CD8+ and CD56+ negatively correlated (r=-0.482/-0.467, P<0.05). Patients with lymph node metastasis or mortality exhibited worse immune/tumor marker profiles than controls (P<0.05). Conclusion: Compared with patients with CIN and chronic cervicitis associated with high-risk HPV infection, cervical cancer patients exhibit decreased systemic immune function and increased circulating tumor marker expression. These findings are closely associated with HPV-DNA levels. Systemic detection of these markers may provide valuable guidance for the early prevention, diagnosis, and prognosis assessment of cervical cancer in patients with high-risk HPV infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.